2 mutations who have HER2-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
https://www.tipranks.com/news/astrazenecas-enhertu-wins-approval-in-eu-by-chmp?utm_source=advfn.com&utm_medium=referral
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jul 2022 bis Aug 2022 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Aug 2021 bis Aug 2022 Click Here for more AstraZeneca Charts.